FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Next >>
 
TXT Ozempic Kidney Study Stopped Due to Efficacy Data
10/11/2023
 
 
TXT No Care Access Issues in VALOR Trial: Company
10/11/2023
 
 
TXT Cytoxan Not Withdrawn Over Safety/Efficacy
10/11/2023
 
 
TXT Multiple Violations in Abiomed Inspection
10/10/2023
 
 
TXT 2 Unapproved GLP-1 Drug Marketers Warned: FDA
10/10/2023
 
 
TXT Suggested Changes to ‘Underrepresented’ Draft Guide
10/10/2023
 
 
TXT ‘Minor Updates’ to 2 Magnetic Resonance Guidances
10/10/2023
 
 
TXT Researcher Cited for ‘Objectionable Conditions’
10/10/2023
 
 
TXT FDA Cautions About Compounded Ketamine
10/10/2023
 
 
TXT FDA QTc Draft Guidance ‘Too Vague’: NCHR
10/10/2023
 
 
TXT CDRH Plans 24 Guidances in FY 2024
10/10/2023
 
 
TXT FDA Diversity Plan Draft Guidance Due: RAPS
10/10/2023
 
 
TXT Positive Keytruda Data in Lung Cancer: Merck
10/10/2023
 
 
TXT Companion Diagnostic for Retevmo Approved
10/09/2023
 
 
TXT Alnylam Gets ‘Complete Response’ on sNDA
10/09/2023
 
 
TXT Biocon Gets Insulin Aspart BLA Rejection
10/09/2023
 
 
TXT ‘Breakthrough’ Status for Knee Implant
10/09/2023
 
 
TXT 11 Dr. Reddy’s ANDAs Withdrawn
10/09/2023
 
 
TXT HistoSonics De Novo for Tumor Blaster
10/09/2023
 
 
TXT AstraZeneca Seeks More Input on Study Diversity
10/09/2023
 
 
TXT Sun Pharma NDA for Alopecia Areata
10/06/2023
 
 
TXT 2 Covid-19 Product EUAs Revoked
10/06/2023
 
 
TXT Senator Urges Justice Probe of Respironics
10/06/2023
 
 
TXT FDA OKs Zoryve Cream Expanded Use
10/06/2023
 
 
TXT Syndax Reports ‘Positive’ Leukemia Data
10/06/2023
 
 
TXT FDA’s Daunting Task to Tackle Misinformation: Califf
10/06/2023
 
 
TXT FDA Clears Home Hemoglobin Test
10/06/2023
 
 
TXT Clinical Hold for Innate Lacutamab Trials
10/05/2023
 
 
TXT CDRH Marks 10 Years of Cybersecurity Program
10/05/2023
 
 
TXT Reps Reiterate Call for VALID Act Passage
10/05/2023
 
 
TXT FDA Looking Into Counterfeit Ozempic: Report
10/05/2023
 
 
TXT Coherus Refiles Udenyca Onbody BLA Supplement
10/05/2023
 
 
TXT AstraZeneca Comments on FDA QTc Draft Guidance
10/05/2023
 
 
TXT Reagan-Udall Strategies to Understand Regulated Products
10/05/2023
 
 
TXT FDA ‘Unsatisfied’ with Philips Respironics Recall
10/05/2023
 
 
TXT Stimulant Use Disorder Treatment Guidance
10/04/2023
 
 
TXT Medtronic Warns on Stolen Laryngoscopes
10/04/2023
 
 
TXT No Safety Issues in Biosimilar Switches: Study
10/04/2023
 
 
TXT ‘Objectionable Conditions’ at Florida Doctor Site
10/04/2023
 
 
TXT Attorney Blasts CDRH for 8,000-day Petition Delays
10/04/2023
 
 
TXT User Fee Courier Delivery Address Change
10/04/2023
 
 
TXT Moderna Phase 3 Trial for Flu/Covid Vaccine
10/04/2023
 
 
TXT Signature Biologics Illegally Marketing Cord Product
10/03/2023
 
 
TXT Repeat CGMP Deviations at Fresenius Unit
10/03/2023
 
 
TXT Oncology Panel to Discuss Accelerated Approvals
10/03/2023
 
 
TXT More Unannounced Inspections in India: Califf
10/03/2023
 
 
TXT FDA Reviewers Question Amgen’s Lumakras Study
10/03/2023
 
 
TXT AdvaMedDx Challenges Oncology Test Pilot
10/03/2023
 
 
TXT FDA Allows Reformulated Novavax Vaccine
10/03/2023
 
 
TXT Galderma Sent Complete Response Letter
10/03/2023
 
 
TXT Guide on 510(k) eSubmission Template
10/03/2023
 
 
TXT Inspection Derails Lilly Eczema BLA
10/02/2023
 
 
TXT Pilot on ANDA Model-Integrated Evidence
10/02/2023
 
 
TXT Case Study in Corruption: Jeff Shuren’s CDRH
10/02/2023
 
 
TXT Novo Nordisk’s Rivfloza OK’d for Rare Disease
10/02/2023
 
 
TXT FDA Clears AI Heart Failure Detector
10/02/2023
 
 
TXT Government Shutdown Likely This Weekend
09/29/2023
 
 
TXT FDA Proposed Rule on Lab-Developed Tests
09/29/2023
 
 
TXT Graft-versus-Host Disease Guidance
09/29/2023
 
 
TXT De Novo Device E-filing Guide
09/29/2023
 
 
TXT Guide on Drug Dose Banding
09/29/2023
 
 
TXT FDA Approves Biogen’s Actemra Biosimilar
09/29/2023
 
 
TXT Generics Office Expands In-person Meetings
09/29/2023
 
 
TXT De Novo e-Submission Template Guidance
09/28/2023
 
 
TXT Petition Seeks Warning on Fluoroquinolone Guides
09/28/2023
 
 
TXT BrainStorm Cell Therapy Rejected by Panel
09/28/2023
 
 
TXT FDA OKs Amicus Pompe Disease Combo Drugs
09/28/2023
 
 
TXT 265 Suicidal Reports on GLP-1 Drugs: Reuters
09/28/2023
 
 
TXT Physiologic Closed-Loop Control Guidance
09/28/2023
 
 
TXT Graft-vs-Host Product Development Guidance
09/28/2023
 
 
TXT FDA OKs Pfizer’s Bosulif for Pediatric CML
09/27/2023
 
 
TXT Ileus Added to Ozempic Label Adverse Effects
09/27/2023
 
 
TXT Gilead Ends AML Trial of Magrolimab
09/27/2023
 
 
TXT Prescription Information Modernization Bill
09/27/2023
 
 
TXT Boston Scientific’s AVVIGO+ Guidance Device Cleared
09/27/2023
 
 
TXT Peace Wellness Marketing Tissue Products: FDA
09/27/2023
 
 
TXT Philips Hid Breathing Machine Complaints: Report
09/27/2023
 
 
TXT Nephron Pharma Hit Again with FDA-483
09/27/2023
 
 
TXT Device QS Cybersecurity Guidance
09/26/2023
 
 
TXT FDA Rejects Anti-Sweating Gel
09/26/2023
 
 
TXT FDA Pushing EG, DEG Testing
09/26/2023
 
 
TXT Guilty Plea in Adulterated HIV Meds Case
09/26/2023
 
 
TXT FDA ‘Cut Corners’ to Approve Hetlioz ANDA: Vanda
09/26/2023
 
 
TXT Upcoming CBER Changes Explained
09/26/2023
 
 
TXT Drug Use Software Guidance Analyzed by Attorneys
09/26/2023
 
 
TXT Novartis Touts Positive Lutathera Phase 3 Data
09/25/2023
 
 
TXT FDA Reviewers Dismiss ALS Therapy Benefit
09/25/2023
 
 
TXT FDA Clears Profound Medical Ablation Module
09/25/2023
 
 
TXT VistaPharm Recalls Sucralfate Lot
09/25/2023
 
 
TXT Coherus Gets Complete Response on Udenyca
09/25/2023
 
 
TXT Manufacturing Resumes at Damaged Pfizer Site
09/25/2023
 
 
TXT FDA Releases Novo Nordisk FDA-483
09/22/2023
 
 
TXT Government, FDA Shutdown Appearing More Likely
09/22/2023
 
 
TXT Guide on Inspection Alternative Tools
09/22/2023
 
 
TXT Senators Urge FDA to Strengthen Opioid Studies
09/22/2023
 
 
TXT Legislation Introduced to Improve Device Recalls
09/22/2023
 
 
TXT Panel Votes Down Intarcia Diabetes Implant
09/22/2023
 
 
TXT PDUFA Formal Meeting Guidance
09/21/2023
 
 
TXT Drug Manufacturing Alternative Assessment Tools
09/21/2023
 
 
TXT Guidance on ISO-10993-1 Explained
09/21/2023
 
 
<< Prev  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving